CSL Behring reported that a meta-analysis supported by the company, revealed that the treatment with albumin reduces renal impairment and mortality in cirrhotic patients with spontaneous bacterial peritonitis. The meta-analysis, which included results from four randomized controlled trials with 288 total patients, found that patients treated with albumin were less likely to develop renal impairment.
Albumin, a natural plasma-derived protein that expands blood plasma volume, is widely used in conjunction with large-volume paracentesis to treat tense ascites, with vasoconstrictors for type 1 hepatorenal syndrome and with antibiotics for spontaneous bacterial peritonitis.
CSL Behring also announced that the first patient has been enrolled in the pivotal pediatric phase III study to evaluate the safety, efficacy and pharmacokinetics of recombinant fusion protein linking coagulation factor IX with recombinant albumin, or rIX-FP, in previously treated children.
CSL Behring, in collaboration with its parent company, CSL Limited, is developing rIX-FP through the PROLONG-9FP clinical trial program for the prophylaxis and treatment of bleeding episodes, including control and prevention of bleeding in surgical settings in patients with factor IX deficiency.
by RTT Staff Writer
For comments and feedback: editorial@rttnews.comBusiness News